Rebecca Weil
Corporate Officer/Principal chez OCULIS HOLDING AG
Postes actifs de Rebecca Weil
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| OCULIS HOLDING AG | Corporate Officer/Principal | 11/09/2023 | - |
Historique de carrière de Rebecca Weil
Anciens postes connus de Rebecca Weil
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| IDORSIA LTD | Sales & Marketing | 01/07/2019 | 01/08/2023 |
| SHIRE | Corporate Officer/Principal | 01/08/2016 | 01/03/2019 |
| Juvenile Diabetes Research Foundation (New York) | Directeur/Membre du Conseil | - | - |
| BAUSCH + LOMB CORPORATION | Sales & Marketing | - | - |
| NOVARTIS AG | Corporate Officer/Principal | - | - |
| ALCON INC. | Corporate Officer/Principal | - | - |
Formation de Rebecca Weil
| Massachusetts Institute of Technology | Doctorate Degree |
| Princeton University | Undergraduate Degree |
Statistiques
Internationale
| Suisse | 5 |
| Etats-Unis | 4 |
| Irlande | 2 |
Opérationnelle
| Corporate Officer/Principal | 4 |
| Sales & Marketing | 2 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 7 |
| Finance | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| OCULIS HOLDING AG | Health Technology |
| IDORSIA LTD | Health Technology |
| ALCON INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| BAUSCH + LOMB CORPORATION | Health Technology |
| Entreprise privées | 2 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
| Juvenile Diabetes Research Foundation (New York) |
- Bourse
- Insiders
- Rebecca Weil
- Expérience
